Corrigendum to <‘Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials’>[J Microbiol Immunol Infect 55 (1) (2022) 26–35]
Shao-Huan Lan,
Chih-Cheng Lai,
Shen-Peng Chang,
Chun-Chun Hsu,
Cheng-Hsin Chen,
Ya-Hui Wang,
Yueh Lan Huang,
Cheng-Yi Wang,
You-Shuei Lin
Affiliations
Shao-Huan Lan
School of Management, Putian University, PR China
Chih-Cheng Lai
Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan
Shen-Peng Chang
Yijia Pharmacy, Tainan, Taiwan
Chun-Chun Hsu
School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
Cheng-Hsin Chen
Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
Ya-Hui Wang
Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
Yueh Lan Huang
Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Corresponding author.
Cheng-Yi Wang
Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Corresponding author.
You-Shuei Lin
Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Corresponding author.
